For example, TGN-020, a selective AQP4 inhibitor, has demonstrated efficacy in reducing cerebral edema and glioma cell migration in animal models, while AER-271, a more recent compound, has shown similar effects with improved pharmacokinetics and CNS penetration (Behnam et al., 2022). The gene discussed is AQP4; the disease is central nervous system cancer.